For individuals interested in weight management, there are several MHRA-authorised and NICE-appraised options available in the UK that do not carry the uncertainties associated with unlicensed compounds
Morieri, M
Three medications represent this progression: Semaglutide (single agonist, 15% average weight loss), Tirzepatide (dual agonist, 22.5% weight loss), and Retatrutide (triple agonist, 28.7% weight loss)
Developed by Eli Lilly, its molecular structure incorporates modified amino acids and a fatty acid side chain designed to extend its duration of action
Unlike inhaled medications that directly contact the oropharyngeal mucosa, tirzepatide is administered subcutaneously and acts systemically through incretin receptor pathways
However, individuals who have obtained or are considering obtaining retatrutide or who are participating in a clinical trial should be aware of specific circumstances that warrant prompt medical attention